Management of Advanced-stage Hypopharyngeal Carcinoma: 25-Year Experience from a Tertiary Care Medical Center.
advanced-stage head and neck cancer
chemoradiation for hypopharyngeal cancer
definitive chemoradiation
definitive surgery
hypopharyngeal carcinoma
laryngeal preservation
retrospective review
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
16 Jan 2020
16 Jan 2020
Historique:
entrez:
28
2
2020
pubmed:
28
2
2020
medline:
28
2
2020
Statut:
epublish
Résumé
Introduction Due to conflicting data in the literature, there is a continuing debate on whether advanced hypopharyngeal carcinoma patients should be treated with definitive surgery or chemoradiotherapy. The purpose of this study is to evaluate the management and outcomes of advanced hypopharyngeal carcinoma in a tertiary care institution over the last 25 years. Methods An Institutional Review Board (IRB)-approved and HIPPA-compliant retrospective analysis was performed of patients with advanced-stage squamous cell carcinoma of the hypopharynx treated at our institution between January 1994 and December 2018. Data regarding demographics, stage, treatment, and follow-up were collected. Outcomes including median survival and overall survival were calculated using the Kaplan Meier method. All analyses were performed using SPSS v. 24. Results This study included a total of 103 advanced stage hypopharyngeal cancer patients. The median age for this cohort is 61 years (range: 41-88, SD 9.3). Of the total 103 eligible patients treated, 92 (89.3%) were male and 11 (10.7%) female; 61 (59.2%) were African Americans, 39 (37.9%) were Caucasians and three (2.9%) were other races. Seventeen patients (16.5%) had stage III disease, whereas 86 (83.5%) patients were diagnosed with Stage IV A or B disease. Seventy-two patients (69.9%) were treated with definitive chemoradiotherapy (ChemoRT group), and 31 patients (30.1%) underwent primary surgery with or without adjuvant treatments (Surgery group). The two treatment groups were similar in terms of age, gender, ethnicity, alcohol status, N staging, and subsites but were significantly different for smoking status (
Identifiants
pubmed: 32104619
doi: 10.7759/cureus.6679
pmc: PMC7026862
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e6679Informations de copyright
Copyright © 2020, Vengaloor Thomas et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Laryngoscope. 1997 May;107(5):648-53
pubmed: 9149168
Acta Oncol. 1994;33(1):55-60
pubmed: 8142126
Auris Nasus Larynx. 2013 Feb;40(1):2-6
pubmed: 22709574
Radiat Oncol. 2010 Oct 07;5:91
pubmed: 20925962
Cancer Med. 2018 Dec;7(12):5889-5900
pubmed: 30479063
Radiother Oncol. 2014 Jan;110(1):16-24
pubmed: 24139733
Anticancer Res. 2018 Jun;38(6):3543-3549
pubmed: 29848708
JAMA Otolaryngol Head Neck Surg. 2015 Jul;141(7):636-40
pubmed: 25973578
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Head Neck. 2018 Nov;40(11):2441-2448
pubmed: 30306665
Acta Otolaryngol. 2008 Jan;128(1):103-9
pubmed: 17851955
Head Neck. 1996 Sep-Oct;18(5):405-11
pubmed: 8864731
Int J Clin Oncol. 2017 Dec;22(6):1001-1008
pubmed: 28624863
Eur Arch Otorhinolaryngol. 2018 Jan;275(1):181-189
pubmed: 29080963
Clin Otolaryngol Allied Sci. 2001 Feb;26(1):59-61
pubmed: 11298170
Laryngoscope. 1997 Aug;107(8):1005-17
pubmed: 9260999
Oral Oncol. 2018 Nov;86:244-250
pubmed: 30409307
J Laryngol Otol. 2018 May;132(5):385-400
pubmed: 29891019
J Natl Cancer Inst. 1996 Jul 3;88(13):890-9
pubmed: 8656441
Clin Otolaryngol Allied Sci. 1995 Jun;20(3):249-53
pubmed: 7554339
Cancer. 2009 Dec 15;115(24):5711-22
pubmed: 19708030